254 related articles for article (PubMed ID: 28445592)
1. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes.
Foca A; Dhillon A; Lahlali T; Lucifora J; Salvetti A; Rivoire M; Lee A; Durantel D
Antivir Ther; 2020; 25(3):151-162. PubMed ID: 32496211
[TBL] [Abstract][Full Text] [Related]
3. Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication.
Wang WH; Studach LL; Andrisani OM
Hepatology; 2011 Apr; 53(4):1137-47. PubMed ID: 21480320
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 is involved in hepatitis C virus replication by hyperphosphorylating NS5A.
Chen YC; Su WC; Huang JY; Chao TC; Jeng KS; Machida K; Lai MM
J Virol; 2010 Aug; 84(16):7983-93. PubMed ID: 20534861
[TBL] [Abstract][Full Text] [Related]
5. Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein.
Studach LL; Menne S; Cairo S; Buendia MA; Hullinger RL; Lefrançois L; Merle P; Andrisani OM
Hepatology; 2012 Oct; 56(4):1240-51. PubMed ID: 22505317
[TBL] [Abstract][Full Text] [Related]
6. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression.
Studach LL; Rakotomalala L; Wang WH; Hullinger RL; Cairo S; Buendia MA; Andrisani OM
Hepatology; 2009 Aug; 50(2):414-23. PubMed ID: 19472310
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production.
Chabrolles H; Auclair H; Vegna S; Lahlali T; Pons C; Michelet M; Couté Y; Belmudes L; Chadeuf G; Kim Y; Di Bernardo A; Jalaguier P; Cosset FL; Fusil F; Rivoire M; Arnold LD; Lopatin U; Combet C; Zoulim F; Grierson D; Chabot B; Lucifora J; Durantel D; Salvetti A
PLoS Pathog; 2020 Nov; 16(11):e1008593. PubMed ID: 33180834
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
10. HBV polymerase overexpression due to large core gene deletion enhances hepatoma cell growth by binding inhibition of microRNA-100.
Huang YH; Tseng YH; Lin WR; Hung G; Chen TC; Wang TH; Lee WC; Yeh CT
Oncotarget; 2016 Feb; 7(8):9448-61. PubMed ID: 26824500
[TBL] [Abstract][Full Text] [Related]
11. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
Tian L; Yao K; Liu K; Han B; Dong H; Zhao W; Jiang W; Qiu F; Qu L; Wu Z; Zhou B; Zhong M; Zhao J; Qiu X; Zhong L; Guo X; Shi T; Hong X; Lu S
Oncogene; 2020 Apr; 39(15):3145-3162. PubMed ID: 32060423
[TBL] [Abstract][Full Text] [Related]
12. Intrahepatic hepatitis B virus large surface antigen induces hepatocyte hyperploidy via failure of cytokinesis.
Li TN; Wu YJ; Tsai HW; Sun CP; Wu YH; Wu HL; Pei YN; Lu KY; Yen TT; Chang CW; Chan HL; Tao MH; Liou JY; Chang MD; Su IJ; Wang LH
J Pathol; 2018 Aug; 245(4):502-513. PubMed ID: 29862509
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
15. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
[TBL] [Abstract][Full Text] [Related]
16. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
18. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
19. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.
Kannan S; Aitken MJL; Herbrich SM; Golfman LS; Hall MG; Mak DH; Burks JK; Song G; Konopleva M; Mullighan CG; Chandra J; Zweidler-McKay PA
Mol Cancer Ther; 2019 Sep; 18(9):1615-1627. PubMed ID: 31227645
[TBL] [Abstract][Full Text] [Related]
20. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
Wäsch R; Hasskarl J; Schnerch D; Lübbert M
Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
